Latest Silibinin Stories
Milk thistle extract has been used since ancient times for liver health and is currently used by many individuals with chronic hepatitis C infections, with only a limited understanding of its
Doctors Health Press, a division of Lombardi Publishing Corporation and publisher of various natural health newsletters, books, and reports, including the popular online Doctors Health Press e-Bulletin,
Use of the botanical product silymarin, an extract of milk thistle that is commonly used by some patients with chronic liver disease, did not provide greater benefit than placebo for patients with treatment-resistant chronic hepatitis C virus (HCV) infection.
On September 12, 2011, a Springfield, Virginia man arrived at MedStar Georgetown University Hospital (MGUH) in the early stages of liver failure.
Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers.
Natural chelator given to victims of Armenian earthquake, Russian nuclear accidents Las Vegas, Nevada (PRWEB) March 27, 2011 A popular hangover prevention supplement may be a safe and effective alternative to potassium iodide for people scrambling to protect themselves from radioactive fallout from Japan's crippled nuclear power plants. The supplement, Cheerz® IntelliShotâ„¢ and iTabsâ„¢, acts as a natural "chelating agent," removing heavy metals including...
By Pradhan, S C; Girish, C Silymarin, a flavonolignan from 'milk thistle' (Silybum marianum) plant is used almost exclusively for hepatoprotection and amounts to 180 million US dollars business in Germany alone. In this review we discuss about its safety, efficacy and future uses in liver diseases.
By Martha Kerr NEW YORK (Reuters Health) - Silibinin, a drug derived from milk thistle, destroys lung cancer in mice, investigators at the University of Colorado, Denver report in the Journal of the National Cancer Institute. Lead investigator Dr. Rana P.